Analysis of the reasons why some patients are not recommended to take mobosertinib (Anvili)

Mobocertinib is an oral tyrosine kinase inhibitor targeting EGFR exon 20 insertion mutations. It is mainly used for patients with advanced or metastatic non-small cell lung cancer (NSCLC). Although it has shown significant efficacy in the treatment of specific mutation types of lung cancer, not all patients are suitable for using the drug. The reasons why some patients are not recommended to take it mainly involve drug tolerance, underlying diseases, concomitant medications and potential side effects.

Mobosetinib may cause significant gastrointestinal side effects, such as diarrhea, nausea, vomiting, and decreased appetite. For patients with poor digestive system function or severe gastrointestinal diseases, these side effects may lead to insufficient nutritional intake, dehydration or even electrolyte imbalance, thereby affecting the overall treatment effect and quality of life, so it is not recommended for such patients.

Mobosetinib may also cause serious adverse reactions such as abnormal liver function, prolongation of QT interval and interstitial lung disease (ILD) during clinical application. Patients with existing liver disease, heart disease, or underlying lung disease are at higher risk of using this drug, which may worsen their condition or cause irreversible damage. Therefore, such patients need to be carefully evaluated and, if necessary, choose other safer treatment options.

Some patients are at risk of drug interactions due to taking other drugs at the same time. Mobosetinib is mainly metabolized by CYP3A. If the patient is taking strong CYP3A inhibitors or inducers, it may lead to abnormal drug concentration, increase toxicity or reduce efficacy. In addition, pregnant women, lactating women and minors are not recommended to use this drug to avoid potential embryo-fetal toxicity or long-term safety issues. Taken together, clinicians need to carefully evaluate whether mobosertinib is suitable for use based on the patient's overall health status, underlying diseases, and concomitant medications.

Reference link:https://www.drugs.com